Multi-Cancer Early Detection Blood Test Offered by GRAIL and Quest Diagnostics
California-based GRAIL, Inc. announced an agreement with Quest Diagnostics (NYSE: DGX) to provide phlebotomy services to support Galleri™, a multi-cancer early detection blood test.
In studies, the Galleri test has shown the ability to detect multiple cancers through a simple blood draw. Most of these cancers cannot be detected through current screening paradigms.
Galleri is available under investigational use in PATHFINDER, GRAIL’s perspective, an interventional study evaluating the implementation of Galleri in clinical practice. Galleri is also expected to be offered to eligible patients in the United Kingdom.
“Today, the majority of cancers go undetected until too late when outcomes are often deadly, and we believe Galleri could offer a unique and potentially life-saving solution by finding multiple types of cancers earlier,” commented Dr. Joshua Ofman, CMO and head of external affairs at GRAIL. “Our agreement with Quest will help us support convenient access to blood collection for patients and healthcare providers.”
Quest Diagnostics maintains approximately 2,200 patient service centers and, through its ExamOne business, 5,000 mobile phlebotomists with expertise in at-home visits. Quest’s phlebotomy network will help provide blood specimen collection for Galleri in the USA once the test becomes available this year.
GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.